Literature DB >> 10442554

Bunina bodies in amyotrophic lateral sclerosis on Guam: a histochemical, immunohistochemical and ultrastructural investigation.

M Wada1, T Uchihara, A Nakamura, K Oyanagi.   

Abstract

An investigation of Bunina bodies is important when studying the pathoetiology and pathomechanisms involved in amyotrophic lateral sclerosis (ALS). It may serve as a clue essential for the study of the pathogenesis of Guamanian amyotrophic lateral sclerosis (ALS-G), and it may provide a means of answering the question of whether ALS-G is the same disease as classical ALS or a different entity. In ALS-G, however, no precise histochemical, immunohistochemical, or detailed ultrastructural examination has been published to date. To elucidate the pathological differences/similarities of Bunina bodies between classical ALS and ALS-G, we performed histochemical, immunohistochemical, topographic and ultrastructural examinations. Histochemically, hematoxylin and eosin, Masson's trichrome, methylgreen-pyronin, phosphotungstic acid-hematoxylin, Klüver-Barrera, Bodian and periodic acid-Schiff staining were utilized. Immunohistochemical examination was performed using antibodies for cystatin C, ubiquitin, Tau-2, Cu/Zn superoxide dismutase, phosphorylated neurofilament and glial fibrillary acidic protein. Histochemical findings were consistent with those previously described for classical ALS. The immunohistochemical study showed that in ALS-G Bunina bodies were intensely labeled by an anti-cystatin C antibody. Topographic examination demonstrated that Bunina bodies were distributed in the spinal anterior horns and Clarke's column in the spinal cord. Ultrastructurally, Bunina bodies were composed of electron-dense amorphous/ granular material accompanied by vesicular structures and neurofilaments. The results of the present study have revealed that the pathological features of Bunina bodies in ALS-G are identical to those seen in classical ALS. These findings strongly suggest that a similar degenerative process occurs in the spinal anterior horn cells in both ALS-G and classical ALS.

Entities:  

Mesh:

Year:  1999        PMID: 10442554     DOI: 10.1007/s004010051063

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  4 in total

Review 1.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

Review 2.  Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update.

Authors:  K Oyanagi; M Wada
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

3.  Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis.

Authors:  A J Whittle; O A Ross; A Naini; P Gordon; H Mistumoto; J C Dächsel; J T Stone; Z K Wszolek; M J Farrer; S Przedborski
Journal:  J Neural Transm (Vienna)       Date:  2006-07-25       Impact factor: 3.575

4.  Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

Authors:  Nils von Neuhoff; Tonio Oumeraci; Thomas Wolf; Katja Kollewe; Peter Bewerunge; Boris Neumann; Benedikt Brors; Johannes Bufler; Ulrich Wurster; Brigitte Schlegelberger; Reinhard Dengler; Marc Zapatka; Susanne Petri
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.